Takeda UK, in partnership with The ADHD Foundation and Eastern AHSN (Academic Health Science Network), is launching a call for applications to our newest digital challenge to benefit patients who have Attention Deficit Hyperactivity Disorder (ADHD). What can Takeda offer?

• Finalists will receive a direct response about collaboration potential at the end of the Innovation Challenge

• Partnership with Takeda UK including potential investment for the winning team(s) for proof-of-concept development in the UK
• Access to mentoring and coaching from Takeda experts from cross functional teams (including medical capabilities, commercial and marketing) to help bring your innovation to fruition
• Benefit from Takeda’s international network of partners and suppliers

Takeda is committed to bringing better health and a brighter future to people worldwide through leading innovation in medicine. As a patient-driven, science-first R&D organization, Takeda combines cutting-edge technologies with a focus on core therapeutic areas: Oncology, Rare Diseases, Neuroscience, Gastroenterology, Plasma-Derived Therapies and Vaccines.

Takeda is accelerating the use of digital and data to speed delivery of life-saving medicines, while also easing the burden of diagnosis and treatment for patients, their families and healthcare providers. Innovation across the entire healthcare ecosystem holds the key to fully unlocking the power of digital and data for improved patient outcomes.

Takeda is proud to be patient-centric and partner-focused. 

To make a bigger impact on peoples’ lives, Takeda is opening its doors to new partnerships that will accelerate the future of personalised healthcare.

ADHD is under recognised/under diagnosed across the UK in all age groups. Solutions could include building disease awareness, digital tools to support HCP screening and assessment or facilitating expert consultation for clinical management, and/or personalised risk prediction.

There is a lack of patient accessible support and monitoring, either face to face or online. This has been further disrupted with COVID 19, meaning that support/education programmes have either been cancelled or delayed. There is also a variation in services provided across the UK, with increased waiting lists to commence treatment plans.